Literature DB >> 7297921

Dose response inhibition in man of meal-stimulated gastric acid secretion by 15(R)-15-methyl prostaglandin E2, given orally.

A Robert, G Kane, S B Reele.   

Abstract

15(R)-15-methyl prostaglandin E2 was given orally to healthy male volunteers. Thirty minutes later a 10% peptone meal was introduced into the stomach, and the acid response was measured by continuous intragastric titration with 0.5 N NaOH for the next two hours. The prostaglandin inhibited acid output in a dose dependent manner; the ED50 (dose inhibiting acid output by 50%) was as little as 10 micrograms per subject (or approximately 140 ng/kg). This compound is the most potent orally active inhibitor of gastric acid secretion in man that is known. It is likely that the antisecretory and cytoprotective properties shared by 15(R)-15-methyl prostaglandin E2 would be beneficial in the treatment of peptic ulcer and in preventing recurrences.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7297921      PMCID: PMC1419868          DOI: 10.1136/gut.22.9.728

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  12 in total

1.  Effect of fat on meal-stimulated duodenal acid load, duodenal pepsin load, and serum gastrin in duodenal ulcer and normal subjects.

Authors:  R A Gross; J I Isenberg; D Hogan; I M Samloff
Journal:  Gastroenterology       Date:  1978-09       Impact factor: 22.682

2.  Methyl-prostaglandin E2 analogues for healing of gastro-duodenal ulcers.

Authors:  J Rybicka; K Gibiński
Journal:  Scand J Gastroenterol       Date:  1978       Impact factor: 2.423

3.  Effect of 15(R)15 methylprostaglandin E2 methyl ester on healing of gastric ulcers. Controlled endoscopic study.

Authors:  W P Fung; S M Karim; C Y Tye
Journal:  Lancet       Date:  1974-07-06       Impact factor: 79.321

4.  Inhibition of gastric secretion by prostaglandins.

Authors:  A Robert; J E Nezamis; J P Phillips
Journal:  Am J Dig Dis       Date:  1967-10

5.  Effect of prostaglandin E1 on gastric secretion and ulcer formation in the rat.

Authors:  A Robert; J E Nezamis; J P Phillips
Journal:  Gastroenterology       Date:  1968-10       Impact factor: 22.682

6.  Effect of orally administered prostaglandin E1 on gastric secretion and gastrointestinal motility in man.

Authors:  E W Horton; I H Main; C J Thompson; P M Wright
Journal:  Gut       Date:  1968-12       Impact factor: 23.059

7.  Inhibition of gastric secretion in man by prostaglandin A.

Authors:  D E Wilson; C Phillips; R A Levine
Journal:  Gastroenterology       Date:  1971-08       Impact factor: 22.682

Review 8.  Gastric antisecretory and antiulcer properties of PGE2, 15-methyl PGE2, and 16, 16-dimethyl PGE2. Intravenous, oral and intrajejunal administration.

Authors:  A Robert; J R Schultz; J E Nezamis; C Lancaster
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

9.  Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury.

Authors:  A Robert; J E Nezamis; C Lancaster; A J Hanchar
Journal:  Gastroenterology       Date:  1979-09       Impact factor: 22.682

10.  Inhibition by prostaglandin E 1 of gastric secretion in the dog.

Authors:  J E Nezamis; A Robert; D F Stowe
Journal:  J Physiol       Date:  1971-10       Impact factor: 5.182

View more
  10 in total

1.  Arbaprostil (15(R)-15-methyl PGE2): lack of effect on theophylline metabolism.

Authors:  S B Reele; A Euler; J McEvers; C Metzler
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

Review 2.  Newer antisecretory agents for peptic ulcer.

Authors:  K W Somerville; M J Langman
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

3.  Oral antisecretory activity of prostaglandin E2 in man.

Authors:  S B Reele; D Bohan
Journal:  Dig Dis Sci       Date:  1984-05       Impact factor: 3.199

4.  Absorption, tissue distribution, and excretion of 3H-labeled arbaprostil in the male rat.

Authors:  A J Sinha; S R Shaw; B A Thornburgh
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Apr-Jun       Impact factor: 2.441

5.  Gastric antisecretory activity of arbaprostil as affected by gastric pH.

Authors:  S B Reele
Journal:  Dig Dis Sci       Date:  1985-07       Impact factor: 3.199

6.  Cytoprotective doses of arbacet with minimal antisecretory properties are not effective in duodenal ulcer healing.

Authors:  D Wengrower; A Fich; E Goldin; R Eliakim; M Ligumsky; D Rachmilewitz
Journal:  Dig Dis Sci       Date:  1987-08       Impact factor: 3.199

7.  Isolation and characterization of the urinary metabolites of arbaprostil in the male dog after intravenous administration.

Authors:  B A Thornburgh; S R Shaw; G E Bronson; A J Sinha
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Apr-Jun       Impact factor: 2.441

8.  Isolation and characterization of urinary metabolites of arbaprostil in the rat.

Authors:  B A Thornburgh; S R Shaw; A J Wickrema Sinha
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Jan-Mar       Impact factor: 2.441

9.  Carbon Monoxide (CO) Released from Tricarbonyldichlororuthenium (II) Dimer (CORM-2) in Gastroprotection against Experimental Ethanol-Induced Gastric Damage.

Authors:  Katarzyna Magierowska; Marcin Magierowski; Magdalena Hubalewska-Mazgaj; Juliusz Adamski; Marcin Surmiak; Zbigniew Sliwowski; Slawomir Kwiecien; Tomasz Brzozowski
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

Review 10.  ANTI-ULCEROGENIC EFFICACY AND MECHANISMS OF EDIBLE AND NATURAL INGREDIENTS IN NSAID-INDUCED ANIMAL MODELS.

Authors:  Weiping Bi; Lizhi Hu; Mao-Qiang Man
Journal:  Afr J Tradit Complement Altern Med       Date:  2017-06-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.